Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-HERCULES Long-term Follow-up Study of Caplacizumab in Acquired TTP
2016-001503-23Phase 3Completed
- Sponsor
- Ablynx
- Start
- Jul 2016
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of caplacizumab in thrombotic thrombocytopenic purpura (TTP), sponsored by Ablynx. Primary endpoints: Proportion of subjects with TTP-related events, Number of TTP-related events and 1 more. Started Jul 2016; status: completed.
02
Drugs
caplacizumab
03
Conditions
thrombotic thrombocytopenic purpura (TTP)
Beyond the preview
Go deeper on 2016-001503-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001503-23.